(Q37857326)

24 August 2017

1 reference

title

Development, clinical evaluation, and post-licensure impact of RotaTeq, a pentavalent rotavirus vaccine (English)

1 reference

24 August 2017

2

Max Ciarlet

1 reference

24 August 2017

Michelle G Goveia

1

1 reference

24 August 2017

Katey E Owen

series ordinal

3

1 reference

24 August 2017

Colette S Ranucci

series ordinal

4

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 March 2011

1 reference

Annals of the New York Academy of Sciences

24 August 2017

published in

1 reference

24 August 2017

volume

1222

1 reference

24 August 2017

page(s)

14-18

1 reference

Global mortality associated with rotavirus disease among children in 2004.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05970.X

Impact of acute rotavirus gastroenteritis on pediatric outpatient practices in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05970.X

Rotavirus vaccines: current prospects and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05970.X

Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05970.X

Rotavirus infection in infants as protection against subsequent infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05970.X

Molecular and biological characterization of the 5 human-bovine rotavirus (WC3)-based reassortant strains of the pentavalent rotavirus vaccine, RotaTeq.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05970.X

Development and application of a quantitative RT-PCR potency assay for a pentavalent rotavirus vaccine (RotaTeq).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05970.X

Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05970.X

Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05970.X

Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05970.X

Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05970.X

Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05970.X

Sustained decline in rotavirus detections in the United States following the introduction of rotavirus vaccine in 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05970.X

Real-world impact of rotavirus vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05970.X

Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05970.X

Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05970.X

Global impact of rotavirus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05970.X

Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05970.X

Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05970.X

Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05970.X

Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05970.X

Prevention of Rotavirus Disease: Updated Guidelines for Use of Rotavirus Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05970.X

10.1111/J.1749-6632.2011.05970.X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference